secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001193125-25-065634
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei reports solnerstotug 14% ORR in PD-(L)1 resistant tumors; Phase 2 planned Q1 2026
--------------------------------------------------------------------------------

- 14% ORR (3/21 evaluable) and 62% DCR in PD-(L)1 resistant 'hot' tumors; nearly 3x historical rechallenge response.
- One durable CR in Merkel Cell Carcinoma (42+ weeks) and two PRs (MCC and MSI-H CRC, 12+ and 36+ weeks).
- All patients with tumor shrinkage remain on study, suggesting potential for deepening responses.
- Solnerstotug well tolerated: no DLTs; mild CRS in 4/60 patients (Grade 1 only).
- Phase 2 initiation expected Q1 2026, subject to sufficient capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525065634/0001193125-25-065634-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312525065634/d831325d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-065634

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer